Last updated: February 21, 2026
What Are the Scope and Claims of GB201519049?
Patent GB201519049 was filed on December 10, 2015, by GlaxoSmithKline (GSK) and published on June 8, 2017. The patent’s primary focus is on a novel class of heteroaryl compounds used as inhibitors of specific biological targets relevant to treatment of diseases such as cancer and inflammasome-related conditions.
Core Claim Features
- Chemical Composition: The patent claims a group of heteroaryl compounds with specified substitutions capable of inhibiting NLRP3 inflammasome activation.
- Therapeutic Application: The compounds are claimed for use in treating or preventing diseases related to inflammasome activation, including neurodegenerative disorders, autoinflammatory diseases, and metabolic syndrome.
- Methods of Synthesis: The patent describes synthetic methods for producing these heteroaryl compounds, emphasizing specific reaction sequences for key intermediates.
- Pharmacological Data: Supporting data claims demonstrate inhibitory activity in cell-based assays, with some in vivo testing in murine models.
Claim Hierarchy
- Independent Claims: Cover the specific heteroaryl structures, generic formulations, and their use in inhibiting NLRP3.
- Dependent Claims: Specify particular substitutions, dosage forms, and method steps.
- Scope Limitations: The claims are limited to compounds with heteroaryl groups having particular substitutions at defined positions, with coverage extending to pharmaceutical compositions and methods of treatment.
Patent Breadth
The patent provides a relatively broad scope, encompassing multiple heteroaryl variants with substitutions designed to optimize binding to the NLRP3 inflammasome. The claim language allows for variations in heteroaryl rings and substitution patterns, which broadens potential infringement coverage.
How Does Patent GB201519049 Fit Into the Larger Patent Landscape?
Similar Patents and Overlap
Key competing patents focus on:
- NLRP3 inhibitors: Several filings by Novartis, AstraZeneca, and other GSK patents explore similar heteroaryl or triazole derivatives.
- Method of Use Claims: Multiple patents claim treatment of inflammasome-related diseases with NLRP3 inhibitors, often overlapping in therapeutic indications.
- Synthetic Methods: Patent filings from different entities emphasize synthetic routes for heteroaryl compounds, sometimes covering core structures similar to GB201519049.
Patent Family and Priority:
GB201519049 is linked to European, US, and other family members, with equivalent applications covering structurally similar compounds. US counterpart applications (e.g., US20170020577) share similar claim scopes, focusing on NLRP3 inhibitors.
Patent Trends
- The patent landscape from 2010 onward shows increased filings on inflammasome inhibitors, especially heteroaryl derivatives.
- Oversight by patent offices reveals common generic claim tactics, including use of Markush structures and functional claiming to broaden coverage.
Legal Status and Enforcement
As of the latest update, GB201519049 remains in force, not subject to opposition proceedings, and has been cited in subsequent patent applications as prior art.
Potential Patent Challenges and Considerations
- Novelty: The core heteroaryl scaffold differs from prior art, but specific substitutions require to be scrutinized to assess novelty.
- Inventive Step: The inventive aspect hinges on an improved inhibitory activity or synthesis method, with the combination of chemical structure and biological data supporting patentability.
- Landscape Overlap: Competing patents with similar compounds may challenge scope. Any attempt to enforce must clearly delineate the structure-activity relationship (SAR) distinctions.
Summary
- The patent claims a broad class of heteroaryl compounds as NLRP3 inflammasome inhibitors.
- Its scope encompasses inventive synthetic methods, pharmaceutical compositions, and treatment methods.
- It operates within a competitive landscape of inflammasome-related patents, with overlapping structures and therapeutic claims.
- Enforcement success relies on maintaining claim novelty and demonstrating functional distinctions over prior art.
Key Takeaways
- GB201519049’s scope is broad in heteroaryl derivatives for inflammasome inhibition, with layered claims covering compounds, uses, and synthesis.
- Its patent landscape includes significant overlap with filings from other major pharmaceutical players targeting NLRP3.
- The patent’s strength depends on the uniqueness of the chemical substitutions and biological data supporting efficacy.
- Overlap with prior art necessitates careful claim differentiation for enforcement.
FAQs
1. What is the main innovation claimed in GB201519049?
A class of heteroaryl compounds designed to inhibit the NLRP3 inflammasome with specific chemical structures and therapeutic applications.
2. How does its scope compare to other inflammasome patents?
It is broad, covering multiple heteroaryl variants and methods, but overlaps exist with patents from other companies focusing on similar targets.
3. Are there active challenges or oppositions against this patent?
No public opposition or legal challenges are recorded for GB201519049 as of now.
4. Which diseases are targeted by the claimed compounds?
Diseases involving inflammasome activation, including neurodegenerative, autoinflammatory, and metabolic disorders.
5. What are key considerations for patent enforceability in this landscape?
Demonstrating structural distinctions and biological efficacy over prior art, especially against overlapping patents from competitors.
References
[1] Patent GB201519049, "Heteroaryl compounds as inflammasome inhibitors," filed by GSK, 2015.
[2] US20170020577, "NLRP3 inflammasome inhibitors," GSK, 2017.
[3] European Patent Application EP3221366, "Heteroaryl derivatives for inflammasome targeting," 2017.
[4] Patent Landscape Report, "Inflammasome inhibitor patents," IQVIA, 2022.
[5] WIPO Patent Information Platform, "Patent families related to NLRP3 inhibitors," 2023.
